Total Payments
$4,050
2024 Payments
$77.86
Companies
13
Transactions
25
Medicare Patients
1,169
Medicare Billing
$118,104
Payment Breakdown by Category
Consulting$3,335 (82.3%)
Food & Beverage$714.88 (17.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,335 | 2 | 82.3% |
| Food and Beverage | $714.88 | 23 | 17.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $3,335 | 2 | $0 (2022) |
| INTERCEPT PHARMACEUTICALS, INC. | $239.67 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $133.22 | 1 | $0 (2023) |
| ABBVIE INC. | $97.75 | 4 | $0 (2024) |
| PFIZER INC. | $77.23 | 5 | $0 (2023) |
| Celgene Corporation | $54.64 | 3 | $0 (2024) |
| Merck Sharp & Dohme LLC | $28.45 | 1 | $0 (2023) |
| Medtronic USA, Inc. | $22.87 | 1 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.06 | 1 | $0 (2019) |
| Phathom Pharmaceuticals, Inc. | $18.82 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $77.86 | 4 | Celgene Corporation ($39.55) |
| 2023 | $424.18 | 11 | E.R. Squibb & Sons, L.L.C. ($133.22) |
| 2022 | $1,727 | 3 | AstraZeneca UK Limited ($1,595) |
| 2020 | $1,758 | 3 | AstraZeneca UK Limited ($1,740) |
| 2019 | $35.64 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($20.06) |
| 2018 | $26.76 | 2 | Medtronic USA, Inc. ($22.87) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/04/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/29/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/19/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.99 | General |
| Category: Neuroscience | ||||||
| 01/18/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.56 | General |
| Category: Neuroscience | ||||||
| 11/28/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/02/2023 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/17/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.09 | General |
| Category: Neuroscience | ||||||
| 07/18/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $32.41 | General |
| Category: IMMUNOLOGY | ||||||
| 07/06/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/21/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: IMMUNOLOGY | ||||||
| 06/13/2023 | PFIZER INC. | XELJANZ (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/31/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $28.45 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/16/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $98.77 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 04/11/2023 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $133.22 | General |
| Category: Neuroscience | ||||||
| 03/30/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 08/18/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $118.54 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 01/31/2022 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/06/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,595.00 | General |
| 12/14/2020 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| 02/27/2020 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Immunology | ||||||
| 02/06/2020 | Romark Laboratories, LC | ALINIA (Drug), ALINIA, ALINIA | Food and Beverage | In-kind items and services | $5.17 | General |
| Category: Gastroenterology | ||||||
| 09/05/2019 | PFIZER INC. | INFLECTRA (Biological) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: INFLAMMATION | ||||||
| 03/05/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Lower GI | ||||||
| 09/17/2018 | Medtronic USA, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 08/07/2018 | Micro-tech Endoscopy USA, Inc. | Sureclip (Device) | Food and Beverage | Cash or cash equivalent | $3.89 | General |
| Category: GI Endoscopy | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 263 | 271 | $186,869 | $29,718 |
| 2022 | 5 | 184 | 185 | $133,571 | $18,995 |
| 2021 | 8 | 375 | 380 | $202,079 | $34,244 |
| 2020 | 9 | 347 | 359 | $175,988 | $35,148 |
Total Patients
1,169
Total Services
1,195
Medicare Billing
$118,104
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 43 | 45 | $47,430 | $6,819 | 14.4% |
| 45390 | Removal of large bowel tissue using a flexible endoscope | Facility | 2023 | 23 | 24 | $16,776 | $6,414 | 38.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 77 | 79 | $73,786 | $6,183 | 8.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 42 | 42 | $12,390 | $4,453 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 36 | $8,568 | $2,934 | 34.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 31 | 31 | $25,203 | $1,955 | 7.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $2,716 | $960.88 | 35.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 42 | 42 | $44,268 | $7,315 | 16.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 62 | 62 | $57,908 | $4,721 | 8.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 31 | 31 | $9,145 | $3,280 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 32 | $7,616 | $2,546 | 33.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 18 | 18 | $14,634 | $1,134 | 7.7% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 55 | 55 | $57,970 | $10,193 | 17.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 83 | 83 | $77,522 | $5,935 | 7.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 49 | 51 | $10,344 | $4,394 | 42.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 38 | 38 | $11,210 | $3,853 | 34.4% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2021 | 50 | 51 | $6,834 | $3,825 | 56.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 37 | 38 | $27,298 | $2,394 | 8.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 13 | 13 | $8,606 | $2,374 | 27.6% |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | Office | 2021 | 50 | 51 | $2,295 | $1,275 | 55.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 44 | 45 | $47,430 | $9,223 | 19.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 80 | 88 | $16,896 | $6,917 | 40.9% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 68 | 68 | $63,512 | $5,622 | 8.9% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2020 | 36 | 37 | $4,958 | $3,700 | 74.6% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2020 | 43 | 45 | $3,150 | $2,309 | 73.3% |
About Weiwei Cao, M.D., PHD
Weiwei Cao, M.D., PHD is a Internal Medicine healthcare provider based in Cedar Park, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1992987283.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Weiwei Cao, M.D., PHD has received a total of $4,050 in payments from pharmaceutical and medical device companies, with $77.86 received in 2024. These payments were reported across 25 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($3,335).
As a Medicare-enrolled provider, Cao has provided services to 1,169 Medicare beneficiaries, totaling 1,195 services with total Medicare billing of $118,104. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location Cedar Park, TX
- Active Since 11/29/2007
- Last Updated 12/23/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1992987283
Products in Payments
- OCALIVA (Drug) $239.67
- ZEPOSIA (Drug) $187.86
- XELJANZ (Drug) $61.65
- RINVOQ (Biological) $54.40
- DIFICID (Drug) $28.45
- VIBERZI (Drug) $23.86
- INTERSTIM (Device) $22.87
- Entyvio (Biological) $20.06
- CREON (Drug) $19.49
- VOQUEZNA (Drug) $18.82
- INFLECTRA (Biological) $15.58
- STELARA (Biological) $13.11
- ALINIA (Drug) $5.17
- Sureclip (Device) $3.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Cedar Park
Dr. Nikhil Agarwal, M.d, M.D
Internal Medicine — Payments: $16,099
Internal Medicine $16,099
Dr. Joshua Reinhart, Md, MD
Internal Medicine — Payments: $8,345
Internal Medicine $8,345
Dr. Nicole Ryman, Md, MD
Internal Medicine — Payments: $5,136
Internal Medicine $5,136
Dr. Ryan Cho, M.d, M.D
Internal Medicine — Payments: $4,835
Internal Medicine $4,835
Dr. Sarika Deshmukh, M.d, M.D
Internal Medicine — Payments: $4,424
Internal Medicine $4,424
Andrew Shaw, M.d, M.D
Internal Medicine — Payments: $4,059
Internal Medicine $4,059